reported a high expression of mesenchymal-to-epithelial transition (MET) in both the primary metastasis and BM of patients with LC and suggested that drugs targeted at MET amplification, such as crizotinib and cabotinib, would have a certain effect on patients with LCBM (42). The gene discussed is MET; the disease is laryngotracheoesophageal cleft.